BCL2 and neoplasm: Similar to cutaneous follicle center lymphoma (PCFCL), tumor cells express BCL6 but are CD10 and BCL2 negative, lack BCL2-R, and carry frequent alteration of TNFRSF14 (60%) without CREBBP and KMT2D mutations [71].